Stock Movers on FDA Decision (SNY, SLXP, ACHN, MRK)

Sanofi-aventis (NYSE: SNY) announces publication of data from the Phase III TROPIC trial of Jevtana (cabazitaxel) Injection. The data was published in The Lancet.

You can Subscribe to these Free Stock Alerts by visiting:  http://www.PennyStockPickReport.com

The study showed that Jevtana in combination with prednisone reduced the risk of death by 30% in men with metastatic castration-resistant prostate cancer whose disease progressed following treatment with a docetaxel-containing treatment regimen.

Salix Pharmaceuticals Ltd. (Nasdaq: SLXP) announces settlement with Novel Labs, who filed an ANDA with the U.S. FDA for a generic version of Salix' OsmoPrep product.

The following is from the 8-K:

CDC III, LLC, owns U.S. Patent No. 5,616,346, or the ‘346 patent. The ‘346 patent is listed with the United States Food and Drug Administration as protecting our OsmoPrep product. CDC licensed OsmoPrep and the ‘346 patent to us for commercialization in the United States. In addition, we own U.S. Patent No. 7,687,075, or the ‘075 patent, protecting OsmoPrep. Novel Laboratories, Inc., filed an ANDA with the FDA seeking approval to market a generic version of OsmoPrep in the United States prior to the May 2013 expiration of the ‘346 patent and the 2024 expiration of the ‘075 patent. On September 8, 2008, we filed a lawsuit in the United States District Court for the District of New Jersey against Novel for the infringement of the ‘346 patent. The lawsuit also joined CDC as a party.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced that they have begun patient dosing in ACH-1625 Phase II. The drug candidate was discovered and is being advanced by Achillion.

ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication.

You can Subscribe to these Free Stock Alerts by visiting:  http://www.PennyStockPickReport.com

Merck & Co., Inc. (NYSE: MRK) announced today that they wou vigorously appeal a Massachusetts federal court jury verdict against Schering-Plough, which alleges that the company caused the Commonwealth of Massachusetts to overpay local pharmacists for prescriptions of albuterol.

Merck was found liable for $4.6 million in damages following a three- week trial.

About http://www.PennyStockPickReport.com

Penny Stock Pick Report offers stock newsletter on OTC, PINKSHEETS ,OTCBB, AMEX, NASDAQ and NYSE stock exchange. Our subscribers receive daily up to date stock information on hot stocks, most active movers, top gainers, penny stocks and much more. If you wish to feature your organization on our website then you can contact us at the email given below.